Introduction

The Rh blood group is the second most important blood group system after ABO, and it is the one that causes most headaches in transfusion medicine and obstetrics. Get it wrong and patients can suffer life-threatening transfusion reactions or babies can be born severely anemic. Get it right and both problems are largely preventable.

This article walks through what the Rh system is, how it's inherited, why it matters clinically, and how laboratories test for it.

The system was first described in 1939 [1]. It now includes more than 50 known antigens, but five do most of the clinical work: D, C, E, c, and e. We will focus on these.

History of the Rh Blood Group System

Before the 1940s, transfusion reactions sometimes happened even when ABO compatibility had been confirmed. Karl Landsteiner and Alexander Wiener, investigating one such case, injected human red cells into rabbits and noticed the resulting antibodies agglutinated red cells from about 85% of people they tested [2].

They initially thought the same antigen existed on rhesus monkey red cells and named the system "Rh." It later turned out the human antigen was different from the rhesus monkey one, but the name stuck. The original monkey-related antigen was renamed "LW" in honor of Landsteiner and Wiener.

Biochemical Composition

Rh antigens sit on two transmembrane proteins (proteins that pass through the red cell membrane) that cross the red cell membrane 12 times. They are made only on red blood cells, which is unusual for blood group proteins. Unlike most blood group antigens, Rh proteins carry no attached sugars.

Their normal function is still debated. Current evidence suggests they act as gas channels, helping carbon dioxide and possibly ammonia move across the membrane [2]. They may also help maintain red cell shape and flexibility.

Genetics of the Rh Blood Group System

Two closely linked genes on chromosome 1 control the Rh system: RHD and RHCE. Together they produce the proteins that carry the D, C, c, E, and e antigens.

The RHD Gene

The RHD gene determines whether a person is RhD-positive or RhD-negative. RhD-positive (D+) is dominant. In most people of European descent, the RhD-negative phenotype comes from a complete deletion of the RHD gene rather than from a "negative allele" [1]. While a complete deletion causes the RhD-negative phenotype in most people of European descent, the genetics differ globally. In people of African ancestry, RhD-negative status is frequently caused by an inherited, inactive RHD pseudogene (RHDΨ). In Asian populations, it is often due to an RHD-CE-D hybrid gene that does not produce the D protein [11]. By convention, geneticists still write the deleted version as a lowercase d, but this is a placeholder. There is no actual d protein and no d antigen.

Inheritance follows standard Mendelian patterns:

• DD or Dd → RhD-positive
• dd → RhD-negative

The RHCE Gene

The RHCE gene sits right next to RHD on chromosome 1. Different versions of it produce proteins carrying either C or c, and either E or e. This is why Rh phenotypes vary so much beyond simple D-positive or D-negative status.

Why So Much Diversity?

The current theory is that RHD and RHCE arose from a gene duplication event in our evolutionary past. They share strong sequence similarity, which is why some RHCE variants make proteins resembling parts of D (the so-called weak D and partial D variants). Mutations within both genes have generated the broad antigen diversity seen across populations.

Rh Nomenclature

Blood banks use two nomenclature systems side by side. Both pre-date the discovery that there are two genes, not three.

Fisher-Race (CDE Notation)

Fisher-Race uses three letters representing the antigens directly: D, C, E (and their absent counterparts c and e). For example, DCe means a haplotype with D, C, and e antigens. This system is the everyday standard in written blood bank records.

Wiener (Rh-r Notation)

Wiener uses single letters with subscripts. R means D is present; r means D is absent.

• R₀ = cDe
• R₁ = CDe
• R₂ = cDE
• Rz = CDE
• r = ce
• r′ = Ce
• r″ = cE
• ry = CE

Wiener is preferred when speaking aloud because "R-one" is faster to say than "D-C-e."

Rosenfield (Numeric)

The Rosenfield system numbers each antigen (D = Rh1, C = Rh2, E = Rh3, c = Rh4, e = Rh5) and uses a minus sign for absence. It is mainly used in research databases and rare-antigen reporting.

Common Haplotype Frequencies

Frequencies vary substantially by ancestry [1,2]:

• European ancestry: R₁ (CDe) is most common at approximately 40–45%, followed by r (ce) at around 37%.
• African ancestry: R₀ (cDe) predominates at approximately 40–45%, with r (ce) at around 36%.
• East and South Asian ancestry: RhD-negative status is rare, often below 1%, so D-positive haplotypes dominate.

These groupings are statistical patterns, not biological categories. Any individual patient should be typed directly, never assumed from background.

Anti-Rh Antibody Production

RhD-negative people don't make anti-D until they are exposed to D-positive red cells. Exposure usually happens in one of two ways: a transfusion of D-positive blood, or pregnancy with a D-positive fetus.

The First Exposure (Sensitization)

After the first exposure, the immune system slowly produces small amounts of anti-D, usually starting as IgM and switching to IgG. This first response is often clinically silent. The danger is what comes next.

The Second Exposure

On re-exposure, memory B cells produce large amounts of IgG anti-D quickly. IgG is the problematic class because it crosses the placenta. In pregnancy, this is what causes hemolytic disease of the fetus and newborn (HDFN).

Other Rh antibodies (anti-c, anti-E, anti-C, and anti-e) can also cause hemolysis. Anti-c is particularly important: it can produce HDFN that is sometimes as severe as anti-D disease [8]. It is also critical to test for the G antigen, which is present on almost all red cells carrying either D or C antigens. In pregnant patients, anti-G looks identical to a mixture of anti-D and anti-C on standard antibody panels. Distinguishing true anti-D from anti-G (with or without anti-C) is vital, because an RhD-negative mother with only anti-G still requires RhIg to prevent actual anti-D sensitization [12].

Rh Blood Typing in the Laboratory

The basic principle is agglutination. Patient red cells are mixed with commercial anti-D antibody. If the D antigen is present, the antibody bridges the cells and they clump visibly.

Tube Method and Solid-Phase Assays

In the classic Rh tyipng tube method, red cells and anti-D are combined, incubated, and read by eye. Modern blood banks more often use gel cards or solid-phase microplate systems, which give clearer endpoints and can be automated.

The Indirect Antiglobulin Test (IAT) for Weak D

Some people carry weak D variants: the D antigen is present but expressed at low levels. Routine testing may miss it. The IAT adds a second antibody (anti-human globulin) that links any anti-D already attached to the cell, making weak agglutination visible.

Why this matters clinically:

• Weak D types 1, 2, and 3 can safely be managed as RhD-positive. They do not need RhIg in pregnancy and can receive RhD-positive blood [10].
• Partial D carriers are missing part of the D protein. They can make anti-D against the missing piece and should be managed as RhD-negative.

RHD genotyping is increasingly used to distinguish these variants when serologic typing is ambiguous [10].

Clinical Significance of the Rh Blood Group 

The Rh blood group matters most in two clinical settings: transfusion and pregnancy.

Hemolytic Transfusion Reactions

When an RhD-negative patient who has already been sensitized receives RhD-positive blood, preformed anti-D destroys the transfused cells. Even a first exposure can cause delayed hemolysis a few days to two weeks later as antibodies develop.

Typical signs and symptoms:

• Fever and chills during or after transfusion
• Back or flank pain
• Hemoglobinuria (dark, tea-colored urine)
• Jaundice
• Hypotension in severe cases

Initial management:

1. Stop the transfusion immediately. Keep the line open with saline.
2. Clerical check of the patient ID and unit label. Mislabeling causes more reactions than antibody errors.
3. Send blood for direct antiglobulin test (DAT), repeat type and crossmatch, plasma free hemoglobin, and bilirubin.
4. Collect urine for hemoglobinuria.
5. Support blood pressure with IV fluids and monitor renal function. Acute kidney injury is the main short-term threat.
6. Watch for disseminated intravascular coagulation (DIC) with PT, aPTT, fibrinogen, and platelet count.

The DAT confirms antibody-coated red cells in the patient's circulation, which is the lab fingerprint of an immune hemolytic reaction.

Hemolytic Disease of the Fetus and Newborn (HDFN)

In an RhD-negative mother carrying an RhD-positive fetus, fetal red cells can leak into the maternal circulation during pregnancy or, more commonly, at delivery. If she has not received RhIg, her immune system makes anti-D. In a subsequent pregnancy with another RhD-positive fetus, that IgG anti-D crosses the placenta and destroys fetal red cells.

The result is fetal anemia, which in severe cases leads to high-output heart failure, generalized edema (hydrops fetalis), and stillbirth. After birth, the breakdown of red cells produces severe jaundice with risk of kernicterus (bilirubin-induced brain injury).

Monitoring Pregnancies at Risk

Modern management has moved away from serial amniocentesis [3,5]:

• First-line: Middle cerebral artery peak systolic velocity (MCA-PSV) Doppler ultrasound. A value greater than 1.5 multiples of the median (MoM) suggests fetal anemia [9].
• Antibody titers are followed throughout pregnancy.
• Amniocentesis (delta OD450) and cordocentesis are reserved for selected cases.

Treatment

• Intrauterine transfusion of compatible red cells when MCA-PSV is elevated or the fetus is hydropic.
• Phototherapy and, in severe cases, exchange transfusion in the newborn to manage hyperbilirubinemia.

Prevention: Anti-D Immunoglobulin (RhIg)

RhIg (also known as RhoGAM or anti-D immunoglobulin) is the prevention story of modern obstetrics. Postpartum RhIg cut alloimmunization rates from roughly 13–16% to 0.5–1.8%, and adding the antepartum dose dropped it further to 0.14–0.2% [4].

Standard dosing in the United States [4,6]:

• 300 μg (1500 IU) at 28 weeks of gestation.
• 300 μg within 72 hours of delivery of an RhD-positive infant.
• Additional doses after sensitizing events: amniocentesis, chorionic villus sampling, antepartum bleeding, abdominal trauma, ectopic pregnancy, miscarriage with instrumentation, and external cephalic version for breech presentation.

The 300 μg dose covers a fetomaternal hemorrhage of up to about 30 mL of whole blood. Larger hemorrhages need a quantitative test (Kleihauer-Betke or flow cytometry) and additional doses. Due to ongoing global supply chain constraints and RhIg shortages, organizations like ACOG advise that if supplies are critically low, practices should prioritize the postpartum dose over the routine 28-week antepartum dose, as the delivery period carries the highest risk of sensitizing fetomaternal hemorrhage [6].

Noninvasive Fetal RHD Genotyping

A newer approach uses cell-free fetal DNA in maternal plasma to determine the baby's RHD status from a simple blood draw, often from 9 weeks of gestation onwards [7]. If the fetus is RhD-negative, RhIg can be safely omitted, sparing the mother an unnecessary injection.

Several European countries (UK, Netherlands, Denmark, Finland, Sweden) have run national programs based on this approach for over a decade. In April 2024, ACOG endorsed cell-free DNA screening for fetal RHD as a reasonable option in practices facing RhIg shortages and for alloimmunized patients who decline amniocentesis [6,7]. Broader adoption in the U.S. is expected.

Quick Reference Tables

When RhIg Is Indicated

Note on early pregnancy loss: International guidelines increasingly differ on RhIg administration for early miscarriages. For example, recent ACOG and NICE updates advise against routine RhIg administration for spontaneous miscarriages occurring before 12 weeks of gestation, prioritizing usage for later gestations or surgical interventions [13].

Weak D vs. Partial D

Frequently Asked Questions (FAQs)

Is O-negative truly the universal blood donor?

O-negative red cells lack A, B, and D antigens, so they're least likely to trigger a reaction in any recipient. That's why they're used in emergencies before a patient's blood type is known. The label is a simplification, though. Other red cell antigens (Kell, Duffy, Kidd) can still cause reactions in patients who have made antibodies to them, which is why a full type and screen is always done when time allows.

What does Rh-positive or Rh-negative actually mean?

It refers to whether the D antigen, a protein on the red blood cell surface, is present. About 85% of people of European ancestry have it (Rh-positive). The other 15% lack it (Rh-negative). The terms come from early experiments using rhesus monkey red cells; the name stuck even though the original interpretation was wrong.

Why do Rh-negative pregnant women need an injection during pregnancy?

If an Rh-negative mother carries an Rh-positive baby, some fetal red cells may enter her bloodstream during pregnancy or delivery. Her immune system can then make anti-D antibodies. In a future pregnancy, those antibodies can cross the placenta and destroy the next baby's red cells. Anti-D immunoglobulin (RhIg, brand name RhoGAM) prevents this by clearing fetal cells before her immune system reacts to them.

Can Rh-negative blood be given to an Rh-positive patient?

Yes, in most cases. Rh-positive recipients tolerate Rh-negative red cells because they don't make antibodies against an antigen they already have. The reverse is not true: giving Rh-positive blood to an Rh-negative person can trigger sensitization. Because Rh-negative blood is scarcer, blood banks generally reserve it for Rh-negative patients and emergencies.

How is Rh typing actually performed in the lab?

The patient's red cells are mixed with commercial anti-D antibody. If the D antigen is present, the cells clump together (agglutinate), giving a positive result. Modern blood banks often use automated gel cards or solid-phase systems for the same purpose. If standard testing is negative but the result is uncertain, an indirect antiglobulin test (IAT) is added to detect weak D variants.

Does Rh incompatibility matter outside of pregnancy and transfusion?

Mostly no. Rh antigens don't appear in other tissues, so they're not relevant for solid organ transplantation in the same way ABO is. The two clinical settings that matter are red cell transfusion and pregnancy.

Glossary of Related Medical Terms

• Agglutination — Visible clumping of red blood cells when antibodies bind to matching antigens on the cell surface. The basis of blood typing.
• Allele — One of the alternative versions of a gene at a specific location on a chromosome.
• Alloimmunization — Development of antibodies against antigens from another person of the same species, usually after pregnancy or transfusion.
• Antigen — A molecule on the cell surface that can be recognized by the immune system. Red blood cell antigens determine blood type.
• Anti-D immunoglobulin (RhIg, RhoGAM) — A purified preparation of anti-D antibodies given to RhD-negative pregnant women to prevent them from making their own anti-D.
• Crossmatch — A pre-transfusion test that mixes donor red cells with recipient serum to confirm compatibility.
• Direct antiglobulin test (DAT, direct Coombs) — A lab test that detects antibodies already attached to red blood cells in the body.
• Erythroblastosis fetalis — An older name for hemolytic disease of the fetus and newborn (HDFN).
• Haplotype — A set of alleles inherited together on the same chromosome.
• Hemolysis — Destruction of red blood cells, releasing hemoglobin into plasma.
• Hemolytic disease of the fetus and newborn (HDFN) — Destruction of fetal or newborn red cells by maternal antibodies that crossed the placenta.
• Indirect antiglobulin test (IAT, indirect Coombs) — A lab test that detects antibodies floating free in plasma that have not yet attached to red cells.
• MCA-PSV Doppler — Middle cerebral artery peak systolic velocity ultrasound; the standard noninvasive test for fetal anemia.
• Partial D — An RhD variant where part of the D protein is missing; carriers can produce anti-D against the missing portion.
• Sensitization — The first immune system encounter with a foreign antigen that primes the body to react more strongly on re-exposure.
• Weak D — An RhD variant with reduced D antigen expression; some types are safely treated as RhD-positive.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Rosenkrans D, Zubair M, Doyal A. Rh Blood Group System. [Updated 2023 Aug 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK594252/
2. Westhoff C. M. (2004). The Rh blood group system in review: a new face for the next decade. Transfusion, 44(11), 1663–1673. https://doi.org/10.1111/j.0041-1132.2004.04237.x
3. Moise K. J., Jr (2008). Management of rhesus alloimmunization in pregnancy. Obstetrics and gynecology, 112(1), 164–176. https://doi.org/10.1097/AOG.0b013e31817d453c
4. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. (2017). Obstetrics and gynecology, 130(2), e57–e70. https://doi.org/10.1097/AOG.0000000000002232
5. ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. (2018). Obstetrics and gynecology, 131(3), e82–e90. https://doi.org/10.1097/AOG.0000000000002528
6. American College of Obstetricians and Gynecologists. (2024). Rho(D) immune globulin shortages: Practice advisory. https://www.acog.org/clinical/guidance/practice-advisory/2024/03/rhod-immune-globulin-shortages/
7. Gilstrop Thompson, M., Xu, W., Moore, B., Wang, T., Sun, N., Pewar, H., Avent, N. D., Vernaza, A., Acosta, F., Saben, J. L., Souter, V., Parmar, S., Sengupta, U., Altug, Y., EmBree, J., Cantos, C., Kotwaliwale, C., Babiarz, J., Zimmermann, B., Swenerton, R., … Meltzer, J. T. (2025). Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort. Obstetrics and gynecology, 145(2), 211–216. https://doi.org/10.1097/AOG.0000000000005794
8. de Haas, M., Thurik, F. F., Koelewijn, J. M., & van der Schoot, C. E. (2015). Haemolytic disease of the fetus and newborn. Vox sanguinis, 109(2), 99–113. https://doi.org/10.1111/vox.12265
9. Mari, G., Deter, R. L., Carpenter, R. L., Rahman, F., Zimmerman, R., Moise, K. J., Jr, Dorman, K. F., Ludomirsky, A., Gonzalez, R., Gomez, R., Oz, U., Detti, L., Copel, J. A., Bahado-Singh, R., Berry, S., Martinez-Poyer, J., & Blackwell, S. C. (2000). Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. The New England journal of medicine, 342(1), 9–14. https://doi.org/10.1056/NEJM200001063420102
10. Sandler, S. G., Flegel, W. A., Westhoff, C. M., Denomme, G. A., Delaney, M., Keller, M. A., Johnson, S. T., Katz, L., Queenan, J. T., Vassallo, R. R., Simon, C. D., & College of American Pathologists Transfusion Medicine Resource Committee Work Group (2015). It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion, 55(3), 680–689. https://doi.org/10.1111/trf.12941
11. Flegel W. A. (2011). Molecular genetics and clinical applications for RH. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 44(1), 81–91. https://doi.org/10.1016/j.transci.2010.12.013
12. Harmening, D. M. (2018). Modern Blood Banking & Transfusion Practices (7th ed.). F.A. Davis Company.
13. National Institute for Health and Care Excellence (NICE). (2026). Ectopic pregnancy and miscarriage: diagnosis and initial management (Update on Anti-D prophylaxis). https://www.nice.org.uk/guidance/ng126